| |
|
|
|
|
| |
|
|
 |
Disfunzione erettile |
|
|
pag 10
BIBLIOGRAFIA
1. US Preventive Services Task Force. Ann Intern Med. 2003; 138:927-937
2. Callahan CM, et al. Med Care 2002;40:771-81
3. Progetto Cronos: i risultati dello studio osservazionale. Bollettino di Informazione sui Farmaci 2004, 5-6:183-188
4. Trinh NH et al. JAMA. 2003; 289:210-216
5. AD2000 Collaborative Group.Lancet 2004; 363: 2105-2115
6. Wilkinson D et al.Neurology 2003; 61:479-86.
7. Lanctot KL et al. CMAJ 2003;169: 557-64
8. Lee PE et al. BMJ 2004; 329:75
9. Sink KM et al. JAMA 2005 Feb 2; 293:596-608
10.Mayor S. BMJ 2005 Feb 5;330:276. http://www.bmj.com/content/330/7486/276.3
11.Gill SS et al.BMJ 2005 Feb 26; 330:445
12.Byrne GJ. Australian Prescriber 2005 Number 3; 28:67–70
13.Petersen RC et al. for the Alzheimer’s Disease Cooperative Study Group. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. N Engl J Med 2005 Jun 9; 352:2379-2388
14.Focus. Bollettino di Farmacovigilanza n. 37, febbraio-maggio 2004. In: http://www.sfm.univr.it/
15.E. Wooltorton. Health and Drug Alerts. CMAJ 2002 Nov 26: 167:1269
16.E. Wolltorton. Health and Drug Alerts. CMAJ 2004 Apr 27, 170:1395
17.MedWatch. 2005 Safety alerts for drugs, biologics, medical devices, and dietary supplements: Reminyl (galantamine hydrobromide). Rockville, Md.: Food and Drug Administration, 2005. In: www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Reminyl.
http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164870.pdf
18. Kaduszkiewicz H et al. Cholinesterase inhibitors for patients with Alzheimer disease: systematic review of randomized clinical trilas. BMJ 2005 Aug 6; 331: 321-327.
19. Singh S et al. Health and Drug Alerts. Increased mortality among elderly patients with dementia using atypical antipsichotics. CMAJ 2005 Aug 2; 173:252.
20. Schneider LS et al. Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomised placebo controlled trials. JAMA 2005 Oct 19; 294:1934-1943.
21. Ballard C, et al. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD003476.
22. Schneider LS et al. for the CATIE - AD Study Group. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. N Engl J Med 2006 Oct 12; 355: 1525-1538
23. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152595.htm
24. Graff MJL et al. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ 2006 Dec 9;333:1196.
25. Gill SS et al. Antipsychotic Drug Use and Mortality in Older Adults with Dementia. Ann Intern Med 2007 Jun 5; 146:775-786
26. Wang PS et al. Risk of Death in Elderly Users of Conventional vs Atypical Antipsychotic Medications. N Engl J Med 2005 Dec 1; 353: 2335-2341
27. Schneeweiss S et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007 Feb 27; 176:627-32
28. Rabins PV et al. Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Am J Psychiatry 164: A48 . Dec. 2007. http://ajp.psychiatryonline.org/cgi/data/164/12/A48/DC2/1
29. Satolli R. L'efficacia dei farmaci per l'Alzheimer. Occhio Clinico 2004. N. 8, pag. 8
|
|
|
|
|
|
|
|
2004 - 2024 © Pillole.org Reg. T. di Roma 2/06 |
 |
 |
ore 16:18 | 1285760 accessi| utenti in linea:
7163
Realizzato con ASP-Nuke 2.0.5
|
